DRI Healthcare Trust (DHT-UN) Q4 2025 earnings summary

Executive summary

• Achieved record financial performance in 2025, with total income of $198.6 million and total cash receipts of $196.4 million, surpassing deployment and royalty income targets, and completing internalization of management to enhance governance and cost efficiency, expected to generate $200 million in synergies over 10 years.

• Deployed and committed over $200 million in 2025, including $87 million deployed and $115 million in contingent commitments, meeting five-year deployment targets and supporting double-digit CAGR in royalty income.

• Returned over $36 million to unitholders via unit repurchases and increased dividends, while reducing preferred share obligations and enhancing capital flexibility.

• Executed a new corporate structure, optimized cost structure, and implemented a proprietary risk assessment framework, driving margin expansion and operational efficiency.

• Positioned for continued growth with a robust pipeline exceeding $3 billion in potential opportunities, leveraging AI integration and a strengthened team.

Financial highlights

• Total income for 2025 reached $198.6 million, up 6% year-over-year; total cash receipts were $196.4 million, up 3%; Adjusted EBITDA for 2025 was $165.0 million, up 5%, with a margin of 84% (normalized to 88% excluding non-recurring costs); Q4 2025 Adjusted EBITDA was $46.2 million with a 91% margin.

• Adjusted cash earnings per unit for 2025 were $2.26; declared cash distributions per unit were $0.40; quarterly distribution increased to $0.11 per unit for Q1 2026.

• Repurchased and canceled 1.4 million units in 2025 for $14.2 million, reducing unit count by nearly 3%.

• Paid total cash distributions of $22.2 million in 2025.

• Comprehensive loss for the year was $51.1 million, impacted by $23.4 million in impairments on Vonjo II and Omidria royalty assets.

Outlook and guidance

• 2026 Adjusted EBITDA guidance set at $157–$162 million, based on a normalized 2025 baseline excluding $15.7 million in non-recurring royalty recoveries.

• Multi-year capital deployment target of $800–$1,000 million for 2026–2030, fully funded by existing capital and cash flows.

• Targeting a low teens CAGR in Adjusted EBITDA through 2030, with sequential acceleration and no need for additional equity.

• Royalty income CAGR tracking at 12% from a 2022 base, above prior high single-digit guidance.

• Increased quarterly distribution to $0.11 per unit for Q1 2026.